Trial Profile
A study to evaluate the elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- 08 Dec 2015 New trial record